A dendritic cell-based assay for measuring memory T cells specific to dengue envelope proteins in human peripheral blood

被引:5
作者
Sun, Peifang [1 ,2 ]
Beckett, Charmagne [1 ]
Danko, Janine [1 ]
Burgess, Timothy [1 ]
Liang, Zhaodong [2 ]
Kochel, Tadeusz [1 ]
Porter, Kevin [1 ]
机构
[1] USN, Med Res Ctr, Dept Viral & Rickettsial Dis, Silver Spring, MD 20910 USA
[2] Henry Jackson Fdn Mil Serv, Rockville, MD USA
关键词
Dengue; Human T cell; Human dendritic cell; Interferon ELISPOT; Dengue E protein; DNA VACCINE; VIRUS; RESPONSES; IMMUNITY;
D O I
10.1016/j.jviromet.2011.01.023
中图分类号
Q5 [生物化学];
学科分类号
071010 ; 081704 ;
摘要
Dengue envelope (E) protein is a dominant immune inducer and E protein-based vaccines elicited partial to complete protection in non-human primates. To study the immunogenicity of these vaccines in humans, an enzyme linked immunospot (ELISPOT) assay for measuring interferon gamma (IFN-gamma) production was developed. Cells from two subject groups, based on dengue-exposure, were selected for assay development. The unique feature of the IFN-gamma ELISPOT assay is the utilization of dendritic cells pulsed with E proteins as antigen presenting cells. IFN-gamma production, ranging from 53-513 spot forming units per million peripheral blood mononuclear cells (PBMCs), was observed in dengue-exposed subjects as compared to 0-45 IFN-gamma spot forming units in dengue-unexposed subjects. Further, both CD4(+) and CD8(+) T cells, and cells bearing CD45RO memory marker, were the major sources of IFN-gamma production. The assay allowed quantification of E-specific IFN-gamma-secreting memory T cells in subjects 9 years after exposure to a live-attenuated virus vaccine and live-virus challenge. Results suggested that the dendritic cell-based IFN-gamma assay is a useful tool for assessing immunological memory for clinical research. (C) 2011 Elsevier B.V. All rights reserved.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 19 条
  • [1] Evaluation of immunity and protective efficacy of a dengue-3 premembrane and envelope DNA vaccine in Aotus nancymae monkeys
    Blair, PJ
    Kochel, TJ
    Raviprakash, K
    Guevara, C
    Salazar, M
    Wu, SJ
    Olson, JG
    Porter, KR
    [J]. VACCINE, 2006, 24 (09) : 1427 - 1432
  • [2] BRODSKY FM, 1991, ANNU REV IMMUNOL, V9, P707
  • [3] CORRADIN G, 1990, IMMUNOL LETT, V25, P11, DOI 10.1016/0165-2478(90)90082-2
  • [4] Phase I trial of 16 formulations of a tetravalent live-attenuated dengue vaccine
    Edelman, R
    Wasserman, SS
    Bodison, SA
    Putnak, RJ
    Eckels, KH
    Tang, D
    Kanesa-Thasan, N
    Vaughn, DW
    Innis, BL
    Sun, W
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06) : 48 - 60
  • [5] Serotype-specific TH1 responses in recipients of two doses of candidate live-attenuated dengue virus vaccines
    Gwinn, W
    Sun, W
    Innis, BL
    Caudill, J
    King, AD
    [J]. AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE, 2003, 69 (06) : 39 - 47
  • [6] DENGUE VIRUSES AND MONONUCLEAR PHAGOCYTES .1. INFECTION ENHANCEMENT BY NON-NEUTRALIZING ANTIBODY
    HALSTEAD, SB
    OROURKE, EJ
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1977, 146 (01) : 201 - 217
  • [7] Guidelines for clinical trials of dengue vaccine in endemic areas
    Hombach, Joachim
    [J]. JOURNAL OF CLINICAL VIROLOGY, 2009, 46 : S7 - S9
  • [8] A dengue virus serotype-1 DNA vaccine induces virus neutralizing antibodies and provides protection from viral challenge in Aotus monkeys
    Kochel, TJ
    Raviprakash, K
    Hayes, CG
    Watts, DM
    Russell, KL
    Gozalo, AS
    Phillips, IA
    Ewing, DF
    Murphy, GS
    Porter, KR
    [J]. VACCINE, 2000, 18 (27) : 3166 - 3173
  • [9] DENGUE VIRUS-SPECIFIC HUMAN T-CELL CLONES - SEROTYPE CROSSREACTIVE PROLIFERATION, INTERFERON GAMMA-PRODUCTION, AND CYTO-TOXIC ACTIVITY
    KURANE, I
    MEAGER, A
    ENNIS, FA
    [J]. JOURNAL OF EXPERIMENTAL MEDICINE, 1989, 170 (03) : 763 - 775
  • [10] Mongkolsapaya J, 2003, NAT MED, V9, P921, DOI 10.1038/nm887